Incyte’s (INCY) “Buy” Rating Reiterated at Raymond James Financial

Raymond James Financial reiterated their buy rating on shares of Incyte (NASDAQ:INCY) in a research report report published on Tuesday morning.

A number of other equities research analysts have also recently issued reports on the company. J P Morgan Chase & Co reiterated a buy rating and set a $149.00 price objective on shares of Incyte in a research note on Thursday, August 31st. Oppenheimer reiterated a hold rating and set a $135.00 price objective on shares of Incyte in a research note on Thursday, August 31st. BMO Capital Markets reiterated an outperform rating and set a $172.00 price objective on shares of Incyte in a research note on Monday, August 28th. Argus reiterated a buy rating and set a $150.00 price objective on shares of Incyte in a research note on Wednesday, September 13th. Finally, Royal Bank of Canada started coverage on Incyte in a research note on Thursday, September 14th. They set a sector perform rating and a $136.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $143.84.

Incyte (NASDAQ:INCY) traded up $0.44 during midday trading on Tuesday, reaching $96.41. The company’s stock had a trading volume of 3,270,325 shares, compared to its average volume of 1,422,630. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. Incyte has a 12-month low of $92.91 and a 12-month high of $153.15.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The company had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. During the same quarter in the prior year, the business posted $0.19 EPS. The business’s revenue was up 41.6% compared to the same quarter last year. equities analysts expect that Incyte will post -1.33 EPS for the current year.

In related news, EVP Reid M. Huber sold 696 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Herve Hoppenot sold 70,502 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 103,620 shares of company stock worth $11,903,297. 17.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC grew its holdings in Incyte by 8.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 236,789 shares of the biopharmaceutical company’s stock valued at $27,643,000 after buying an additional 18,234 shares in the last quarter. IFM Investors Pty Ltd acquired a new position in Incyte in the 3rd quarter valued at $567,000. Piedmont Investment Advisors LLC acquired a new position in Incyte in the 3rd quarter valued at $503,000. California Public Employees Retirement System grew its holdings in Incyte by 2.8% in the 3rd quarter. California Public Employees Retirement System now owns 359,272 shares of the biopharmaceutical company’s stock valued at $41,941,000 after buying an additional 9,672 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Incyte in the 3rd quarter valued at $542,000. 90.86% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Incyte’s (INCY) “Buy” Rating Reiterated at Raymond James Financial” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/16/incytes-incy-buy-rating-reiterated-at-raymond-james-financial.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit